Mechanism of Ticagrelor-Induced Dyspnea
The most widely accepted mechanism by which Brilinta (ticagrelor) causes shortness of breath is through inhibition of adenosine reuptake by red blood cells, leading to increased circulating adenosine levels that trigger respiratory sensations. 1
Primary Mechanism: Adenosine Accumulation
Ticagrelor inhibits the human equilibrative nucleoside transporter 1 (hENT1) on erythrocytes, which normally clears adenosine from the circulation 1. This results in:
- Elevated systemic adenosine concentrations that amplify and prolong adenosine receptor activity 2
- Adenosine-induced effects on respiratory centers and sensory pathways
- The dyspnea is typically mild to moderate, dose-related, and self-limiting 3
The FDA label confirms that approximately 14-21% of patients develop dyspnea, with discontinuation rates of 0.9-6.9% depending on the study 3. Importantly, pulmonary function testing shows no adverse effects on lung function, indicating the dyspnea is not due to actual respiratory compromise 3.
Alternative and Emerging Hypotheses
Neuronal P2Y12 Receptor Inhibition
A competing hypothesis suggests that reversible P2Y12 inhibition on sensory neurons may increase dyspnea sensation 4. This theory is supported by:
- All reversible P2Y12 inhibitors (ticagrelor, cangrelor, elinogrel) cause dyspnea
- Irreversible inhibitors like clopidogrel do not cause this effect
- Neurons can rapidly replace inhibited receptors, but reversible inhibitors maintain constant blockade with repeated dosing 4
Novel Mechanisms Under Investigation
Recent research (2025) proposes hyperactivity of the retrotrapezoid nucleus in the ventral medulla as an alternative explanation 5. Additionally, ticagrelor may increase peripheral serotonin (5-HT) levels by upregulating tryptophan hydroxylase 1 and downregulating serotonin transporters, potentially contributing to tracheal effects 6.
Clinical Implications
Key management points:
- Dyspnea typically occurs early in treatment and often resolves spontaneously without intervention 3
- No specific treatment is required; continue ticagrelor if dyspnea is tolerable 3
- Pulmonary function remains normal despite symptoms 1
- If intolerable, consider switching to another P2Y12 inhibitor (clopidogrel or prasugrel)
Important caveat: The adenosine hypothesis has been challenged because dipyridamole (a much stronger adenosine reuptake inhibitor) rarely causes dyspnea 4, and elinogrel (structurally unrelated to adenosine) also causes dyspnea 7. This suggests the mechanism may be more complex than adenosine accumulation alone.
Patients at higher risk:
- Those with asthma or COPD may be more susceptible 2
- Monitor these patients closely for adherence and symptom tolerance
The dyspnea does not compromise the cardiovascular benefits of ticagrelor, which include reduced mortality, MI, and stroke compared to clopidogrel 1, 3.